Screening for plasma uric acid is widespread in many countries including Italy. This is based on the assumption that alongside gout, hyperuricemia may be associated with and contribute to several cardiovascular, renal, and metabolic disorders, although evidence of the clinical utility of such routine screening is still scant.1
Article InformationCorresponding Author: Carla Carnovale, PharmD, Unit of Clinical Pharmacology, “Luigi Sacco” University Hospital, Via GB Grassi, 74, 20157 Milan, Italy (email@example.com).
Published Online: May 5, 2014. doi:10.1001/jamainternmed.2014.1427.
Conflict of Interest Disclosures: None reported.
Funding/Support: This study was supported by the Italian Medicines Agency (AIFA) and the Centre of Pharmacovigilance of Regione Lombardia (ViGer project, Vigilanza in Geriatria [Dr Clementi]) and the Italian Ministry of Health (RC 2013 [Dr Clementi]).
Role of the Sponsor: The sponsors had no role in the preparation, review, or approval of the manuscript or the decision to submit the manuscript for publication.
Additional Contributions: Sonia Radice, BioID (Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital “Luigi Sacco,” Università di Milano) and Paolo Pellegrino, MD (Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences, University Hospital “Luigi Sacco,” Università di Milano) assisted in the coordination and supervision of the work. They did not receive any compensation for such contributions.